Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2015 Nov;21(11):1883-7. doi: 10.1016/j.bbmt.2015.09.005. Epub 2015 Sep 11.

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

Author information

1
Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington. Electronic address: jdeeg@fredhutch.org.
2
Ottawa Hospital Research Institute at University of Ottawa, Ottawa, Canada.
3
National Marrow Donor Program, Minneapolis, Minnesota.
4
Hematology/Oncology Division, Massachusetts General Hospital, Boston, Massachusetts.
5
Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
6
Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, Arizona.
7
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
8
Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
9
Section of Hematology/Oncology, University of Manitoba, Winnipeg, Canada.
10
Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.
11
Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington.

Abstract

Myeloproliferative neoplasms (MPN) are chronic marrow disorders with variable prognoses. Most patients with polycythemia vera, essential thrombocythemia, or even primary myelofibrosis (PMF) are successfully treated with conservative strategies for years or even decades, and recent data suggest that even in patients with high-risk disease, in particular those with PMF, life expectancy can be extended by treatment with janus kinase (JAK2) inhibitors. However, none of those modalities are curative, and after marrow failure develops, the disease "accelerates," or transforms to acute leukemia, the only option able to effectively treat and, in fact, cure MPN is allogeneic hematopoietic cell transplantation (HCT). Outcome is superior if HCT is performed before leukemic transformation occurs. Several reports document survival in unmaintained remission beyond 10 years. The most recent analyses show reduced regimen-related mortality (less than 10% or even 5% at day 100) and progressively improved survival with both HLA-identical sibling and unrelated donors. The development of low/reduced-intensity conditioning regimens has contributed to the improved success rate and has allowed successful HCT in patients in their seventh and even eighth decade of life. We propose, therefore, that HCT should be offered to fit patients in these age groups and should be covered by their respective insurance carriers.

KEYWORDS:

Essential thrombocythemia; Hematopoietic cell transplantation; Myeloproliferative neoplasms; Polycythemia vera; Primary myelofibrosis

PMID:
26371371
PMCID:
PMC4604067
DOI:
10.1016/j.bbmt.2015.09.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center